Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

Abstract: The invention relates to a process for preparing polymethylolated melamine and polymethylolated melamine compounds polyetherified with alkanol, wherein the methylolation reaction is carried out in a kneading reactor.

Abstract: The invention relates to a process for preparing polymethylolated melamine and polymethylolated melamine compounds polyetherified with alkanol, wherein the methylolation reaction is carried out in a kneading reactor.

Abstract: In a process for preparing alkoxycarbonylaminotriazines, di- or triaminotriazines are reacted with cyclic carbonic esters and optionally with minor amounts of acyclic carbonic esters in the presence of an alcohol and of an alkali metal alkoxide or alkaline earth metal alkoxide as a base.

Abstract: The invention relates to an aqueous impregnating resin solution containing (A) between 77.5 and 99.8 wt. %, in relation to the impregnating resin solution, of aqueous condensates based on melamine and formaldehyde; (B) between 0.1 and 20 wt. %, in relation to the impregnating resin solution, of at least one specific quaternary ammonium compound; and (C) between 0.1 and 2.5 wt. %, in relation to the impregnating resin solution, of an aqueous hardener solution. The invention also relates to an aqueous impregnating resin solution consisting of constituents (A) and (B), and to an aqueous hardener mixture consisting of constituents (B) and (C). The invention further relates to an impregnating resin film containing fibrous substances containing cellulose and impregnated with the aqueous impregnating resin solution, and to the use of the aqueous impregnating resin solution, or impregnating resin film, for the antistatic finishing of coated materials.

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: The invention concerns a novel construct for expressing a gene coding for a recombinant protein of interest placed under the control of the Ptrp tryptophan operon promoter in a procaryotic host cell. The invention is characterised in that the construct comprises a nucleic sequence capable of inactivating the gene coding for a TnaA tryptophanase when said nucleic sequence is introduced in said host cell. The invention also concerns vectors containing said construct and host cells transformed by said vectors. The invention further concerns methods for producing said recombinant proteins using said novel constructs.

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: The invention concerns pharmaceutical composition comprising in a pharmaceutically acceptable medium at least a peptide derived from a periplasmic domain of an enterobacterium Omp protein or a nucleic construct coding for said peptide, as well as the use of such a peptide or such a nucleic construct for the preparation of a vaccine for prophylactic or therapeutic treatment of viral, bacterial, parasitic or fungal infections, or for preparing a vaccine designed for the prophylactic or therapeutic treatment of cancers.